Activated University of Michigan as The Second Site for Clinical Trial in Severe Esophageal Disease

Stock Information for Harvard Apparatus Regenerative Technology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Harvard Apparatus Regenerative Technology Inc.

Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia
Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial
Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.